Musi wa22 Chivabvu, 2025, Allist Pharmaceuticals yakazivisa kuti mushonga wayo mutsva weAiruikai (Glecirasib Citrate Tablets), mushonga unodzivirira KRAS-G12C, wabvumidzwa zviri pamutemo kuti utange kushandiswa neNational Medical Products Administration (NMPA). Kubvumidzwa uku kunobvumira Airuikai kushandiswa pakurapa varwere vakuru vane KRAS®®G12C-mutated advanced non-small cell lung cancer (NSCLC) avo vakambogamuchira kanenge nzira imwe chete yekurapa mumuviri. Izvi zvinoratidza imwe nzira itsva yekurapa kenza yemapapu yakatenderwa kuAllist Pharmaceuticals, ichipa sarudzo itsva yekurapa varwere vane KRASG12C-mutated non-small cell lung cancer (NSCLC) uye ichibatsira kugadzira patsva mamiriro ekurapa kwerudzi urwu rwekenza yakaoma kurapa.
Kubvumidzwa uku kwakavakirwa pamhedzisiro yeongororo yakakosha yePhase II single-arm inoongorora kuchengetedzeka, kushivirira, uye kushanda kweGlecirasib monotherapy muvarwere vane kenza yemapapu isiri diki ine KRASG12Cmutations vakakundikana kana kuti vakanga vasingashiviriri kurapwa kwakajairika.
Zvakabuda zvakaratidza kuti Goleresai inoshanda uye inoshivirira varwere zvakanaka. Kubva musi wa28 Gunyana, 2024, varwere veNSCLC vanosvika 119 vakaverengerwa muongororo iyi. Muyero wemhinduro yakasimbiswa (cORR), sezvakaongororwa neIndependent Review Committee (IRC), waiva 49.6% (40.2%-59.0%), nechiyero chekutonga chirwere (DCR) che86.3% (78.7%-92.0%). Nguva yemhinduro yepakati (DOR) yaive mwedzi 14.5 (mwedzi 9.6 kusvika isingafungidzike), kurarama kwepakati pasina kufambira mberi (PFS) kwaive mwedzi 8.2 (5.2–11.1), uye kurarama kwepakati (OS) kwaive mwedzi 17.5 (mwedzi 13.6 kusvika isingafungidzike).
Parizvino, kuchine miedzo yakawanda yekiriniki yehunyanzvi hutsva hwekurwisa gomarara muChina huri kutsvaga varwere. Kana muchida kubvunzana nezvemishonga mitsva netekinoroji, munogona kubata Dhipatimendi reBeijing South Region Oncology Hospital International.
Nhamba yefoni: 4008803716
Email：myimmnet@163.com
Nguva yekutumira: Chivabvu-27-2025